Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Biotechnology

Healthcare
$298.71 +1.10%

+$2.89 today

Market cap
$5.98B
Beta
1.04
P/E (TTM)
34.4
EPS (TTM)
$7.72
52W Low $110.00High $268.43

Volume 0.38M

Average 0.22M

LGND Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Ligand Pharmaceuticals IncorporatedNASDAQ: LGND

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables turns positive

Q2 FY2026 accounts payables was $3.25M, compared with -$407K a year earlier. Trailing-twelve-month accounts payables was $14.4M.

Context

  • Accounts payables amounted to 2.2% of revenue in FY2025, up 2.2 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $3.25M or moves back toward the trailing-twelve-month quarterly average of $3.6M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.25M+19.6% QoQ
Last fiscal yearDec 2025
$5.88M— YoY
LTMJun 2026
$14.4M+31.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+897.5%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
5.88M USD
Year-over-year change
—

Accounts Payables vs competitors

How LGND compares with its peers on the latest reported figures

  • LGND's LTM Jun 2026 accounts payables of $14.4M is the 6th largest of the 10 companies compared; the peer median is $532K.
  • Its year-over-year change of +31.4% is the 3rd highest of 8, against a peer median of -48.5%.
  • Accounts payables amounts to 5.0% of revenue for LGND, versus a peer median of 0.4%.
LGND Competitors Peer median
Accounts Payables for LGND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABBVAbbVie Inc.LTM Jun 2026$740M -44.5%-16.0%1.1%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$450M +533.8%—0.9%
AMGNAmgen Inc.LTM Jun 2026$157M -121.4%+40.6%0.4%
GMABGenmab A/SLTM Jun 2026$37.17M —+12.3%0.9%
INCYIncyte CorporationLTM Jun 2026$34.69M -48.5%-60.4%0.6%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$14.4M +31.4%—5.0%
EXELExelixis, Inc.LTM Jul 2026$8.01M -69.6%—0.3%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$532K +110.0%+0.6%0.2%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$458K -90.0%—0.0%
PFEPfizer Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding LGND) $532K-48.5%+0.6%0.4%

Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income57.14M(33.36M)52.15M(4.03M)124.45M
Depreciation & Amortization50.95M43.39M36.52M35.24M33.78M
Deferred Income Tax(8.62M)20.72M11.7M(15.8M)22.68M
Stock-Based Compensation38.78M60.29M25.74M41.09M0
Change in Working Capital(52.16M)65.68M(34.4M)19.36M(12.67M)
Accounts Receivables(28.62M)55.32M(2.6M)(6.46M)(21.74M)
Inventory(427K)12.06M(10.87M)9.62M4.99M
Accounts Payables(1.17M)(3.34M)(4.7M)05.88M
Other Working Capital(21.96M)1.64M(16.23M)16.2M(1.8M)
Other Non-Cash Items(7.29M)(18.87M)(42.14M)21.2M(118.89M)
Operating Cash Flow78.8M137.85M49.58M97.05M49.36M
Capital Expenditures(8.76M)(17.92M)(53.85M)(19.64M)(452K)
Acquisitions (Net)494K(750K)(25.65M)(172.19M)(8.09M)
Purchases of Investments(181.33M)(51.23M)(126.76M)(226.38M)(730.86M)
Sales of Investments221.34M234.39M194.17M269.62M377.28M
Other Investing Activities(1.22M)(868K)(49.91M)(12.89M)(4.34M)
Investing Cash Flow30.52M163.62M(11.68M)(143.66M)(377.32M)
Debt Repayment(146.01M)(260.8M)(76.9M)(25K)338.11M
Common Stock Issued33.76M3.23M22.45M37.14M114.89M
Common Stock Repurchased(18.45M)000(15M)
Dividends Paid00000
Other Financing Activities(7.07M)(18.42M)(5.5M)60.03M(9.77M)
Financing Cash Flow(137.76M)(275.99M)(59.95M)97.14M428.22M
Effect of Forex Changes000(1.17M)2.36M
Net Change in Cash(28.44M)25.48M(22.05M)49.35M102.62M
Free Cash Flow70.04M119.93M(4.27M)77.41M48.91M

Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Intrinsic Alpha fair value

Locked

Current Price

$298.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.